Malaria affects millions of individuals in tropical and subtropical regions of the world and infection with *Plasmodium falciparum* continues to cause an economic burden in several areas ( [@B38] ) and to cause death among non-treated individuals, particularly children, non-immune travellers and pregnant women ( [@B45] ). Approximately 219 million cases of malaria and 660,000 deaths were reported worldwide in 2010 ( [@B46] ).

Medicinal plants offer an alternative in treating malaria, particularly among populations exposed to endemic transmission in sub-Saharan African countries and in certain regions of Latin America ( [@B10] , [@B49] , [@B1] , [@B2] ). Although synthetic drug combinations are the basis for malaria treatment in Brazil, plants are still used as remedies in the Amazon and elsewhere and represent a potential source for compounds in the development of new antimalarial drugs ( [@B21] ).

Due to the spread of drug-resistant parasites globally, the treatment of malaria is becoming increasingly difficult ( [@B44] ). Thus, the identification of safe and selective antimalarial drugs derived from plants has been stimulated by the World Health Organization and is a research priority of several groups, including ours ( [@B23] , [@B22] , [@B3] ). Indeed, medicinal plants afforded the discovery in the XIX century of the first remedies from the bark of *Cinchona* spp, later shown to be rich in alkaloids, particularly quinine, the basis of such aminoquinoline synthetic drugs as chloroquine, amodiaquine and mefloquine. Another class of important antimalarials is based on artemisinin, a compound found in *Artemisia annua* , a medicinal plant native to China ( [@B43] ). Unfortunately, clinical failures have also been reported in patients with *P. falciparum* treated with artemisinin derivatives in the recommended artemisinin combined therapy ( [@B47] ).

The testing of products from medicinal plants in animal models and in parasite cultures has resulted in the identification of potent molecules, as recently reviewed ( [@B23] , [@B21] , [@B4] ). An example is *Cecropia pachystachya* (Cecropiaceae), which is used against fever and malaria in several parts of Latin America, with tormentic acid and beta-sitosterol shown to be responsible for the antimalarial activity ( [@B41] ). Other examples include *Aspidosperma nitidum* (Benth) and *Aspidosperma* *excelsum* (Muell Arg), widely cited as remedies in the treatment of malaria, among other species of the genus *Aspidosperma* (Apocynaceae), which comprises various medicinal species used as bark infusions against malaria and other diseases ( [@B11] , [@B42] , [@B18] , [@B39] , [@B14] ).

Reviews on the chemistry of *Aspidosperma* plants cite indole alkaloids ( [@B35] , [@B20] ) and a new alkaloid, braznitidumine, from *A. nitidum* was described, isolated and characterised by one of the present authors ( [@B29] ). In this study, we verify the biological activity of wood bark extracts and fractions in vitro against chloroquine-resistant (CQR) *P. falciparum* parasites and in a *Plasmodium berghei* -infected mouse malaria model *.*

MATERIALS AND METHODS
=====================

*Plant materials -* Wood bark, branches and leaves were harvested between 2004-2012 from the same adult tree ( [Fig. 1](#f01){ref-type="fig"} ) growing at the Federal University of Amazonas farm located in Manaus, state of Amazonas, Brazil. A plant voucher coded 181832 has been deposited at the National Institute of Amazon Research herbarium. Using the plant material collected in 2004, a new alkaloid molecule named braznitidumine was previously described by one of the present authors (MMP) ( [@B29] ).

Fig. 1: *Aspidosperma nitidum* , a medicinal plant named *carapanaúba* , from which the wood bark material was collected and used to prepare extracts and fractions that displayed high antimalarial activity and low toxicity, in vitro and in vivo.

*Extraction and chromatographic profiles of the active fractions -* The materials of *A. nitidum* were dried, powdered and extracted using previously described protocols ( [@B28] ). The wood bark powder (2 kg) was divided into two equal parts: one was extracted by static maceration with ethanol (EtOH) for seven days at room temperature (RT) and the other with methanol (MeOH). After solvent removal by rotary evaporation, 23.4 g (2.3%) and 32 g (3.2%) of the EtOH and MeOH-A crude extracts, respectively, were obtained. The EtOH crude extract and the chloroform and ethyl acetate fractions obtained were used for the biological tests described.

A new sample of wood bark (1 kg) was extracted with MeOH by maceration with agitation at 40ºC for 48 h and yielded 34.4 g (3.4%) of the crude extract (MeOH-B). Extracts of the wood bark, leaves and branches were also prepared using either the Soxhlet technique (EtOH and acetone) or maceration at RT with agitation (EtOH and water).

The wood bark collected in 2012 (1.5 kg) was macerated at RT with 1.6 L of MeOH for 48 h to yield, after solvent removal, 85.5 g (5.7%) of MeOH-C crude extract. This extract was then subjected to an acid-base fractionation protocol to obtain alkaloid-rich fractions ( [Fig. 2](#f02){ref-type="fig"} ). The yields of each fraction are also shown in [Fig. 2](#f02){ref-type="fig"} . The shaded box indicates the biological activity and positive reaction with Dragendorff's reagent.

Fig 2: fractionation scheme of *Aspidosperma nitidum* methanolic wood bark extract and its fractions showing activity against malaria parasites highlighted in the boxes. AcOEt: ethyl acetate; CHCl ~3~ : chloroform; HCl: hydrochloric acid; MeOH: methanol.

The MeOH-C crude extract and its fractions (FO III, FO IV and precipitate) were subjected to a chromatographic analysis using a high performance liquid chromatography (HPLC) in with a Shimadzu apparatus (Shimadzu Co, Kyoto, Japan) composed by of a pump (model LC-10AD) and diode array detector (model SPDM20A) scanning from 200-500 nm, controlled by a CBM 20A. The samples were injected into a 20-l loop coupled to a Rheodyne (IDEX Health & Science, Oak Harbor, WA, USA) valve and analysis separated over with an Ascentis RP18 column (Supelco Inc, Bellefonte, PA, USA) with a particle size of 5 micrometers. The mobile phase was a: MeOH-water (both with 0.1% formic acid) gradient from 30-50% in 20 min, reaching 100% MeOH at 25 min. The data were acquired and analysed using the software LC-Solutions (Shimadzu North America, Columbia, MD, USA).

*Antimalarial tests against P. berghei in mice -* The protocol for animal use was approved by the Ethical Committee (CEUA LW-23/13) at the Oswaldo Cruz Institute.

A previously described antimalarial suppressive test in mice ( [@B36] ) was slightly modified ( [@B12] ). Briefly, Swiss outbred adult female mice, 20 ± 2 g, were inoculated with *P. berghei* by an intraperitoneal route *,* 1 × 10 ^5^ freshly infected red blood cells (iRBC) per animal, using either chloroquine-sensitive (CQS) (NK65) or CQR parasites selected by successive treatment ( [@B24] ). Two-24 h later, the mice were randomly distributed and subjected to drug treatment by an oral route once a day for three consecutive days. Two control groups were used: one not treated and another treated with chloroquine (either 15 mg/kg for animals with CQS parasites or 100 mg/kg for animals with CQR parasites).

The plant extracts and fractions were freshly diluted with 3% dimethyl sulphoxide (DMSO) in water immediately before gavage using different doses in a 200-μL volume per animal. Blood smears were prepared at the fifth and seventh days after parasite inoculation, MeOH-fixed, stained with Giemsa and examined microscopically for parasitaemia determination.

The inhibition of parasite growth (IPG) in the treated groups was evaluated by a comparison with the level of parasitaemia in the non-treated mice using the equation IPG = 100 minus the mean parasitaemia in the treated mice, multiplied by 100 and divided by the mean parasitaemia in the non-treated controls. The compounds reducing parasitaemia by 40% or more were considered active, those reducing 30-40% as partially active and reductions of less than 30% as inactive.

*Continuous cultures of P. falciparum and antiplasmodial tests -* CQR and mefloquine-sensitive *P. falciparum* , clone W2 ( [@B33] ), was cultivated using the candle jar method ( [@B40] ), with minor modifications ( [@B7] ). The continuous culture was maintained in human erythrocytes (A ^+^ ) at 37ºC in complete medium (RPMI-1640 supplemented with 10% human sera blood group A ^+^ ), which was changed daily. The human erythrocytes (A ^+^ ) and serum blood group A ^+^ were kindly donated by the Centre of Haemotherapy and Haematology of Minas Gerais under a mutual cooperation agreement (protocol 18/09). 

Immediately prior to the tests, the blood parasites were concentrated through sorbitol synchronisation of the ring stages ( [@B25] ). The blood suspension was adjusted for parasitaemia and haematocrit according to the specifications for each test, then distributed (180 µL/well) into 96-well microtitre plates (Corning, Santa Clara, CA, USA) containing the diluted extracts, fractions and braznitidumine (20 µL/well) in triplicate for each dose. Chloroquine, the standard antimalarial, was tested in parallel each time.

The activity of the plant extracts and fractions against *P. falciparum* was determined relative to the control cultures without antimalarial drugs as described (Rieckmann et al. 1978) and measured as follows: (i) the anti-HRPII test previously described (Noedl et al. 2002), (ii) the \[ ^3^ H\]-hypoxanthine incorporation assay ( [@B16] ) with slight modifications ( [@B50] ) or (iii) quantitative tests based on optical microscopy, here referred to as the traditional test ( [@B37] ).

For the anti-HRPII test, the *P. falciparum* cultures were adjusted to 1.5% haematocrit and 0.05% parasitaemia; anti-HRPII monoclonal antibodies were commercially acquired from ICLLAB (Stuart, FL, USA) (MPFM-55A and MPFG-55P) and the TMB chromogen (3,3′,5,5′-tetramethylbenzidine) was acquired from KPL (Gaithersburg, MD, USA). After stopping the reaction with 50 μL/L of 1 M sulphuric acid, the absorbance was measured at optical density (OD) 450 nm using a spectrophotometer (SpectraMax ^340^ PC ^384^ ) (Molecular Devices, Sunnyvale, CA, USA).

For the \[ ^3^ H\]-hypoxanthine incorporation assay, *P. falciparum* cultures were maintained in a medium without hypoxanthine for at least four days and the haematocrit and parasitaemia were adjusted to 1% . \[ ^3^ H\]-hypoxanthine (0.5 μCi) was acquired from PerkinElmer (Waltham, MA, USA). After 42 h of incubation with the drug, the cells were harvested \[Tomtec 96-Harvester (Tomtec Inc, Handem, CT, USA)\] on glass-fibre filters (Wallac Ou, Turku, Finland), placed in sample bags (Wallac) and immersed in scintillation fluid (Optiphase super mix, Wallac). The radioactive emission was counted using a 1450 Microbeta reader (Wallac).

For the traditional test, a suspension of RBCs with 1% parasitaemia, previously synchronised, was distributed into a 96-well microtitre plate (100 µL/well) and cultured in complete medium (RPMI-1640 containing 10% human serum, 2% glutamine and 7.5% NaHCO ~3~ ). After 48 h, blood smears were prepared, coded, stained with Giemsa and examined at 1,000X magnification. The parasitaemia of the controls (considered as 100% growth) was compared to that of the test cultures and the percentage IPG was calculated.

For all tests, the extracts and fractions were dissolved in aqueous DMSO (0.02%) stock solution and the antiplasmodial activity was calculated by comparing the IPG in the drug-exposed cultures to that in the drug-free control culture. In tests performed using serial drug dilutions, sigmoid dose-response curves were generated with curve-fitting software (Microcal Origin Software v.5.0), which enabled the determination of the 50% inhibitory concentration (IC ~50~ ).

*Cytotoxicity tests -* The human hepatoma cell line (HepG2) was originally received from the New University of Lisbon and the monkey kidney cell line (BGM) was obtained from the Federal University of Minas Gerais. The cells were cultured in 75-cm ^2^ plates with RPMI-1640 medium supplemented with 10% heat-inactivated foetal calf serum and 40 mg/L gentamicin in a 5% CO ~2~ atmosphere at 37ºC. For the in vitro tests, a confluent cell monolayer was trypsinised, washed with culture medium, distributed in a flat-bottomed 96-well plate (5 x 10 ^3^ cells/well) and incubated for 18 h at 37ºC to ensure cell adherence.

Cytotoxicity was evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Denizot & Lang 1986) assay. Briefly, the HepG2 and BGM cell lines were incubated with 20 µL of the extracts and fractions at different concentrations (1,000-15 µg/mL) for 24 h in a 5% CO ~2~ and air atmosphere at 37ºC. For the MTT assay, which evaluates mitochondrial viability, 20 µL of MTT solution (5 mg/mL) was added and the plates were incubated for another 3 h. After incubation, the supernatant was carefully removed from the wells, followed by the addition of 100 µL DMSO, with thorough mixing. The OD at 570 nm and 630 nm (background) was determined using an ELISA reader (SpectraMax ^340^ PC ^384^ ).

The cell viability was expressed as the percentage of control absorbance obtained from the untreated cells after subtracting the absorbance from the appropriate background. The minimum lethal dose for 50% of the cells (MLD ~50~ ) was determined as previously described ( [@B27] ). This value was used to calculate the selectivity index (SI) defined by the ratio between the MDL ~50~ and IC ~50~ values ( [@B9] ).

*Statistical analysis -* The data are expressed as the mean ± standard deviation for the in vivo tests. The statistical significance of the survival curves was evaluated by an ANOVA test followed by a Bonferroni post-test and the mean parasitaemia by a Student's *t* test followed by a Mann-Whitney *U* post-test. Both analyses were performed using GraphPad Prism 5.0 software. Only p \< 0.05 or less was considered statistically significant.

RESULTS
=======

The plant material in the present study was collected between 2004-2012 from the *A. nitidum* specimen shown in [Fig. 1](#f01){ref-type="fig"} . Extracts from the wood bark, leaves and branches were prepared and evaluated in biological assays with *P. falciparum* and mice infected with *P. berghei* in addition to assays to evaluate cytotoxicity. The EtOH crude extract of the wood bark collected in 2004 and its fractions, as obtained through liquid-liquid partitioning, were able to reduce the parasitaemia in mice infected with *P. berghei* by 55% ( [Table I](#t01){ref-type="table"} ). These are the same extracts and fractions used in a previous chemical investigation that resulted in the identification of several compounds, including harman-3-carboxylic acid and braznitidumine ( [@B29] ) which was inactive against *P. falciparum* in vitro (data not shown).

TABLE IParasitaemia and reduction in mice inoculated with *Plasmodium berghei* infected erythrocytes after oral treatment daily, for three consecutive days, with *Aspidosperma nitidum* ethanolic wood bark extract and its fractionsPlant extract and ethanol fractions used for mice treatment by oral route ^*a*^Dose (mg/kg)Mice parasitaemia n (% reduction) ^*b*^ActivityDay 5Day 7Crude ethanolic extract12511 (48)25 (49)Yes25011 (48)22 (55)YesChloroform fraction12517 (19)33 (33)Partial25012 (43)18 (63)YesEthyl acetate fraction12518 (14)36 (27)No25016 (24)30 (39)PartialChloroquine (control drug)150 (100)10 (80)YesNon-treatedNone21 (0)49 (0)Control*a* : crude extract and fractions obtained through liquid-liquid partition (Marques et al. 1996) using the plant wood bark collected in 2004; *b* : reduction of parasitaemia calculated in relation to control infected non-treated mice (n = 3 mice for treated groups and n = 4 mice for non-treated control group).

None of the crude extracts or fractions was cytotoxic to HepG2 or BGM cells; the MDL ~50~ values of all the crude bark extracts and fractions were similar or better when tested on normal cells, with the exception of FO IV ( [Table II](#t02){ref-type="table"} ).

TABLE IICytotoxicity of *Aspidosperma nitidum* extracts and fractions against a monkey kidney cell line (BGM) and a human hepatoma cell line (HepG2) determined by MTT expressed as the minimal lethal dose for 50% of cells (MDL ~50~ )Crude extracts and fractionsMDL ~50~ (µg/mL) mean ± SDBGMHepG2Bark extracts ^*a*^ Ethanolic≥ 2000654 ± 40 Methanolic-A964 ± 1.4255 ± 9 Methanolic-B≥ 2000≥ 1000 Methanolic-C427 ± 243600 ± 14Fractions from MeOH-C ^*b*^ Fraction FO III301 ± 17562 ± 18 Fraction FO IV89 ± 53169 ± 50 Precipitate≥ 20001103 ± 371Leaves extracts Ethanolic≥ 2000≥ 1000 Acetonic≥ 2000≥ 1000 Aqueous≥ 2000≥ 1000Branches extracts Ethanolic≥ 2000280 ± 30 Aqueous≥ 2000≥ 1000*a* : the different crude extracts were prepared from plant material by static maceration at room temperature \[methanol (MeOH)-A and MeOH-C\] or by maceration with agitation at 40°C (MeOH-B); *b* : fractions from MeOH-C were obtained through an acid-base liquid-liquid partitioning protocol to produce alkaloid-rich fractions (Fig. 2); MTT: (2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide; SD: standard deviation. Three tests were performed with each cell line.

The crude plant extracts showed significant antimalarial activity. Thus, new plant material from this specimen was collected and extracts were prepared for further fractionation and in vitro tests against *P. falciparum* , as shown in [Table III](#t03){ref-type="table"} . The data showed that the *A. nitidum* crude extracts and fractions had similar IC ~50~ values in the traditional test (data not shown), \[ ^3^ H\]-hypoxanthine incorporation and anti-HRPII test with monoclonal antibodies. The most active extracts were those obtained from the wood bark, whereas those from the branches and leaves were inactive or only slightly active (EtOH crude extract of leaves) ( [Table III](#t03){ref-type="table"} ). The best activity was observed with the crude extracts from the wood bark, with IC ~50~ values between 4.6-12.4 µg/mL. The calculated SI, a ratio between toxicity and activity in vitro, varied from 24-152.

TABLE IIIIn vitro activity of *Aspidosperma nitidum* extracts and fractions against *Plasmodium falciparum* blood forms measured as the dose inhibiting 50% inhibitory concentration \[(IC ~50~ ) in µg/mL\] of parasite growth and selectivity index (SI), a ratio between cytotoxicity and activity \[lethal dose for 50% of cells (MDL ~50~ )/IC ~50~ \]Crude extracts and fractions\[ ^3^ H\]-hypoxanthineAnti-HRPIIIC ~50~ mean ± SD ^*b*^SI ^*a*^IC ~50~ mean ± SD ^*b*^SI ^*a*^BGMHepG2BGMHepG2Bark extracts Ethanolic7 ± 3286834.6 ± 4.4435126 Methanolic-A8.3 ± 1.61163110.7 ± 1.39024 Methanolic-B10 ± 3.62001006.6 ± 2.2303152 Methanolic-C12.4 ± 1.9344810.8 ± 0.44056Fractions from MeOH-C ^*c*^ Fraction FO III1.6 ± 0.06188392.3 ± 1.57030 Fraction FO IV3.3 ± 0.430514.8 ± 2.11935 Precipitate5.5 ± 0.23642017.6 ± 4.4263145Leaves extracts Ethanolic22 ± 0.7912925.3 ± 6.07925 Acetonic≥ 50Inactive≥ 50Inactive Aqueous≥ 50Inactive≥ 50InactiveBranches extracts Ethanolic≥ 50Inactive≥ 50Inactive Aqueous≥ 50Inactive≥ 50Inactive*a* : SI based on the results of cytotoxicity shown in Table II (SI ≤ 10 is indicative of toxicity); *b* : the samples considered active had IC \< 12 µg/mL (partially active had 12-20 µg/mL and \> 20 µg/mL were considered inactive); *c* : fractions from methanol (MeOH-C) were obtained through an acid-base liquid-liquid partitioning protocol to produce alkaloid-rich fractions (Fig. 2); BGM: monkey kidney cell line; HepG2: hepatoma cell line. Three tests were performed with each methodology.

The acid-base liquid-liquid partition of the MeOH-C extract afforded three alkaloid-rich fractions (FO III, FO IV and precipitate) that were active against *P. falciparum,* with IC ~50~ values as low as 1.6 µg/mL (for FO III). These fractions showed a positive reaction with Dragendorff's reagent and their analysis by HPLC-DAD confirmed the presence of braznitidumine in each ( [Fig. 3](#f03){ref-type="fig"} ). Regardless of the in vitro assay used, the IC ~50~ values were low, ranging from 1.6-5.5 µg/mL in the \[ ^3^ H\]-hypoxanthine assay, 2.3-7.6 µg/mL in the anti-HRPII assay and 2.8-6.8 µg/mL in the traditional test. None of the fractions was toxic to either HepG2 or BGM cells. Among the three fractions tested, the highest SI was found with the precipitate, which showed values of 200 in HepG2 and 364 in BGM cells in the \[3H\]-hypoxanthine assay and 145 (HepG2) and 263 (BGM) in the anti-HRPII assay ( [Table III](#t03){ref-type="table"} ).

Fig. 3: extracted chromatograms comparison at 254 nm of MeOH crude extract (A) and fractions, precipitate (B), FO III (C) and FO IV (D).

The alkaloid-rich fractions were tested in mice infected with *P. berghei* and were active in two independent experiments ( [Table IV](#t04){ref-type="table"} ). The MeOH-C crude extract reduced *P. berghei* parasitaemia by up to 67% with the dose of 100 mg/kg; the FO III, FO IV and precipitate fractions, at 50 mg/kg, also reduced parasitaemia by 66%, 65% and 57%, respectively. Although a dose of 100 mg/kg decreased parasitaemia to a slightly reduced extent for unclear reasons, survival was significantly increased in the mice treated with the MeOH-C crude extract and precipitate and in the mice receiving 50 mg/kg of the FO III and FO IV fractions ( [Table IV](#t04){ref-type="table"} ).

TABLE IVAntimalarial activity of *Aspidosperma nitidum* extracts and fractions from wood barks against *Plasmodium berghei* in mice in one experiment evaluated seven days after intraperitoneal infection induced by blood parasitesMice group treated with ^*a*^Dose (mg/kg)Parasitaemia mean ± SD (% reduction) ^*b*^Mice survival in days (mean ± SD)Non-treatedNone2.2 ± 0.422.8 ± 2.7Treated with    MeOH-C ^*c*^1000.7 ± 0.2 (67)24.2 ± 3.9 ^*d*^ Fraction FO III500.7 ± 0.3 (66)21.4 ± 2.3 ^*d*^1001.1 ± 0.6 (48)22.8 ± 5.0 Fraction FO IV500.8 ± 0.2 (65)21.4 ± 2.3 ^*d*^1001.0 ± 0.9 (54)23.0 ± 4.5 Precipitate500.9 ± 0.5 (57)23.8 ± 4.31001.0 ± 0.3 (53)24.2 ± 2.0 ^*d*^*a* : treatment with extracts and fractions from the plant barks collected in 2012; *b* : reduction of parasitaemia in relation to control untreated mice (n = 5); *c* : fractions from methanol (MeOH)-C were obtained through an acid-base liquid-liquid partitioning protocol to produce alkaloid-rich fractions (Fig. 2); *d* : p \< 0.05 in relation to the non-treated control group; SD: standard deviation.

In another independent experiment using mice infected with *P. berghei* CQR, the EtOH crude extract was protective at a dose of 125 mg/kg, with the best results on the fifth day after inoculation, with 54% reduction in parasitaemia ( [Table V](#t05){ref-type="table"} ). Although chloroquine significantly reduced parasitaemia and increased survival, it was not curative in the mice treated with a high dose (100 mg/kg) compared with the untreated control mice ( [Fig. 4](#f04){ref-type="fig"} ).

TABLE VActivity of ethanolic crude extract from wood bark of *Aspidosperma nitidum* against *Plasmodium berghei* chloroquine-resistant in mice after treatment during three consecutive days in parallel with the antimalarial chloroquineTreatment withDose (mg/kg)Parasitaemia mean ± SD (% reduction) ^*a*^Day 5Day 7Control non-treated02.6 ± 0.7 (0)5.2 ± 2.3Chloroquine1000.9 ± 0.3 (65)3.7 ± 0.6 (29)EtOH crude extract  62.51.8 ± 0.5 (31)3.9 ± 0.2 (25)1251.2 ± 0.5 (54)3.3 ± 0.4 (37)2501.4 ± 1 (46)4.8 ± 1 (8)*a* : reduction of parasitaemia calculated in relation to control infected non-treated mice (n = 4); SD: standard deviation.

Fig. 4: mean parasitaemia by *Plasmodium berghei* in mice infected with chloroquine-resistant parasites following treatment for three consecutive days with the test compounds, evaluated on the fifth (A) and seventh (B) days after inoculation. EtOH: ethanol.

The potential of the active MeOH and EtOH crude wood bark extracts to induce mutagenic and genotoxic effects was evaluated with Ames tests ( [Ames et al. 1975](#t05){ref-type="table"} ). The tests were performed at the Genotox-Royal Institute, state of Rio Grande do Sul, Brazil (contract GT00752 and GT00719) using five strains of *Salmonella typhimurium* with different mutations at concentrations of up to 3,000 µg/plate. The plant extracts were tested in the absence and presence of the metabolising rat liver fraction and none exhibited a potential for mutagenicity or genotoxicity.

DISCUSSION
==========

Plants have been used throughout history as remedies in most cultures and are the basis for many pharmaceuticals currently in use. It is estimated that 80% of the tropical and subtropical populations of the world depend on herbal remedies to treat diseases and sources of new, safer and effective compounds with medicinal properties are investigated ( [@B48] ). Several antimalarial formulated phytomedicines have been proposed as possible alternatives to costly and, therefore, unaffordable therapies ( [@B49] ); however, this practice occurs to a lesser extent in Brazil, as the Ministry of Health provides specific diagnoses and synthetic antimalarials ( [portal.saude.gov.br/portal/arquivos/pdf/guia_pratico_tratamento_malaria_brasil_2602.pdf](http://portal.saude.gov.br/portal/arquivos/pdf/guia_pratico_tratamento_malaria_brasil_2602.pdf) \]. Nonetheless, several reference laboratories are located in and outside the malaria-endemic areas that are targeted for control (portal.saude.gov.br/portal/arquivos/pdf/centros_de_referencia.pdf).

A recent broad compilation of plant species reported in the worldwide literature cites plants as treatments for fever and/or malaria and the names of 1,277 species in 160 families are listed; among these, 956 species belonging to 140 plant families are found in the Amazon alone ( [@B49] ). In Brazil, a country with great biodiversity and rich ethnic and cultural diversity, the traditional knowledge of medicinal plants has been reported and medicinal plants have been investigated ( [@B11] , [@B8] , [@B14] , [@B30] ), as previously reviewed ( [@B21] , [@B21] , [@B3] ), constituting important sources that should be better explored.

Different native populations exposed to malaria transmission in the Amazon Region (including Brazil, Venezuela, Colombia and Guiana) and other Latin American countries use plant remedies as antimalarials, e.g., in Colombia ( [@B19] , [@B26] ) and Bolivia ( [@B31] ) and among traditional healers in Brazil ( [@B12] ).

Among *Aspidosperma* species, *A. excelsum* and *A. nitidum* are widely cited as curative relative to fever and malaria ( [@B11] , [@B14] ) and communities living in areas of the state of Pará cite *A. nitidum* and *A. rigidum* (Rusby) and "Indian beer" or *Ampelozyziphus amazonicus* (Rhamnaceae) as antimalarials. Although "Indian beer" has been proven to act as a prophylactic in rodent malaria, in mice with sporozoite-induced infection and in vitro with sporozoite cultures ( [@B6] ), its various crude extracts were clearly proven to be inactive against blood parasites in vitro and in vivo ( [@B23] ). Crude extracts and fractions from other *Aspidosperma* species native to regions outside the malaria transmission area (in the state of Minas Gerais) have been proven to be active against malaria blood parasites ( [@B34] , [@B17] ). Similarly, extracts from *Aspidosperma* *vargasii* and *Aspidosperma* *desmanthum* were also shown to be active and are believed to be a source of economically affordable drugs against malaria.

The present work confirms that crude extracts from the wood bark of *A. nitidum* show intense activity against malaria parasites in mice. Indeed, wood bark is the part of the plant used to prepare infusions to treat malaria in the Amazon Region. Based on our present results that the pure alkaloid braznitidumine described in the plant ( [@B29] ) was inactive in vitro, it is probable that a mixture of alkaloids detected in the active fractions of the crude extract of this plant are responsible for the antimalarial activity. New tests with braznitidumine need to be performed in mice, but this trial will require a large amount of this alkaloid, which is difficult to obtain.

In conclusion, the active *A. nitidum* crude bark extract showed the best activity against malaria parasites, the lowest cytotoxicity in vitro and no potential for mutagenicity or genotoxicity. Other species with proven antimalarial activity, such as *Aspidosperma* *ramiflorum* , *Aspidosperma* *pyrifolium* , *Aspidosperma* *olivaceum* , *Aspidosperma* *macrocarpon* and *Aspidosperma* *tomentosum* , have a lower therapeutic index, but have resulted in the chemical characterisation of new compounds systematically tested in vitro for anti- *P. falciparum* activity, with a low cytotoxicity and a less impressive therapeutic index (our unpublished observations). The alkaloids from several of these species have been characterised and shown to be active against *Leishmania* sp. parasites ( [@B13] ). *A. nitidum* was by far the most active species, a finding that makes this traditional remedy useful for the control of malaria. However, further studies are required for drug development, as the present data indicate that the activity of the fractions and extracts may be due to a mixture of alkaloids rather than a single substance (braznitidumine). Nevertheless, drug mixtures are known to be important for delaying the appearance of drug-resistant malaria parasites.
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